Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Editor

Personal info

View

About

Terms

Javascript disabled

Please enable Javascript support in your browser to use this application.

Instructions on how to enable JavaScript on different browsers can be found here: http://www.google.com/support/bin/answer.py?answer=23852.

[edit this page]

Chemical Compound Review:

Motesanib N-(3,3-dimethyl-1,2- dihydroindol-6-yl)-2...

Synonyms: QCR-80, PubChem22412, AMG-706, AGN-PC-00DRCB, AMG706, ...

Blumenschein, G.R. et al., Kruser, T.J. et al., Coxon, A. et al.

Timothy O'Rourke, Yining Ye, G. Joe Stephenson, George R. Blumenschein, Jesse McGreivy, Alan Sandler, Mandy Parson, Gregory Gladish, Yu-Nien Sun, Karen Reckamp,

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Motesanib

These data suggest that motesanib may have broad utility in the treatment of human breast cancer [1].
Motesanib significantly enhanced intratumoral hypoxia in the presence and absence of fractionated radiation [2].

Associations of Motesanib with other chemical compounds

Treatment with motesanib was tolerable when combined with carboplatin/paclitaxel and/or panitumumab, with little effect on motesanib pharmacokinetics at the 125-mg once daily dose level [3].

References

Broad antitumor activity in breast cancer xenografts by motesanib, a highly selective, oral inhibitor of vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors. Coxon, A., Bush, T., Saffran, D., Kaufman, S., Belmontes, B., Rex, K., Hughes, P., Caenepeel, S., Rottman, J.B., Tasker, A., Patel, V., Kendall, R., Radinsky, R., Polverino, A. Clin. Cancer Res. (2009) [Pubmed]
Augmentation of radiation response by motesanib, a multikinase inhibitor that targets vascular endothelial growth factor receptors. Kruser, T.J., Wheeler, D.L., Armstrong, E.A., Iida, M., Kozak, K.R., van der Kogel, A.J., Bussink, J., Coxon, A., Polverino, A., Harari, P.M. Clin. Cancer Res. (2010) [Pubmed]
Phase 1b study of motesanib, an oral angiogenesis inhibitor, in combination with carboplatin/paclitaxel and/or panitumumab for the treatment of advanced non-small cell lung cancer. Blumenschein, G.R., Reckamp, K., Stephenson, G.J., O'Rourke, T., Gladish, G., McGreivy, J., Sun, Y.N., Ye, Y., Parson, M., Sandler, A. Clin. Cancer Res. (2010) [Pubmed]

Contributions to this collaborative article are from individual authors of WikiGenes or mined by the WikiGenes Data Mining Engine from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenes Open Access Licence Privacy Policy Terms of Use apsburg

The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

Editor

Share